Industrial, Manufacturing & Heavy Industry Market News

Pipeline review of of glial cell line derived neurotrophic factor just published

This study covers geographic analysis and important players/vendors such as GlaxoSmithKline Plc, Treeway BV, UniQure NV etc.

- Advertisement -
- Upgrade your free trial to WhaTech Pro to remove advertising -

Glial Cell Line Derived Neurotroph…c Factor or GDNF) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glial Cell Line Derived Neurotrophic Factor - Pipeline Review, H2 2017, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request a sample report @ www.htfmarketreport.com/sample-rep…urotrophic-factor

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors.

- Advertisement -
- Upgrade your free trial to WhaTech Pro to remove advertising -
It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons.

The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.  The molecules developed by companies in Phase II and Preclinical stages are 2 and 4 respectively.

Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Ophthalmology which include indications Amyotrophic Lateral Sclerosis, Parkinson's Disease, Brain Ischemia, Neurodegenerative Diseases and Retinal Degeneration.

Furthermore, this report also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Access report @ www.htfmarketreport.com/buy-now?fo…amp;report=694220

Advantages of report


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned in the Report

GlaxoSmithKline Plc
Treeway BV
UniQure NV

Access report @ www.htfmarketreport.com/request-di…urotrophic-factor

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
The Report Coverage 5
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview 6
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/69…urotrophic-factor
 
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.